GeneHealth - Your precision medicine

Mastocytosis

Disease Details

Family Health Simplified

Buy Membership

Description: Mastocytosis is a disorder characterized by an abnormal accumulation of mast cells in the skin and other tissues, which can lead to a variety of symptoms including skin lesions, itching, and anaphylaxis.
Type: Mastocytosis is a clonal disorder characterized by the abnormal accumulation of mast cells in various tissues. It can be classified primarily into two types: cutaneous mastocytosis and systemic mastocytosis.

The genetic transmission of mastocytosis is typically sporadic, but familial cases have been reported, suggesting a potential autosomal dominant inheritance pattern with variable expression. In many cases, it is associated with mutations in the KIT gene, which encodes a receptor tyrosine kinase involved in cell signaling.
Signs And Symptoms: When mast cells undergo degranulation, the substances that are released can cause a number of symptoms that can vary over time and can range in intensity from mild to severe. Because mast cells play a role in allergic reactions, the symptoms of mastocytosis often are similar to the symptoms of an allergic reaction. They may include, but are not limited to
Fatigue
Skin lesions (urticaria pigmentosa), itching, and dermatographic urticaria (skin writing)
"Darier's Sign", a reaction to stroking or scratching of urticaria lesions.
Abdominal discomfort
Nausea and vomiting
Diarrhea
Olfactive intolerance
Ear/nose/throat inflammation
Anaphylaxis (shock from allergic or immune causes)
Episodes of very low blood pressure (including shock) and faintness
Bone or muscle pain
Decreased bone density or increased bone density (osteoporosis or osteosclerosis)
Headache
Depression
Ocular discomfort
Increased stomach acid production causing peptic ulcers (increased stimulation of enterochromaffin cell and direct histamine stimulation on parietal cell)
Malabsorption (due to inactivation of pancreatic enzymes by increased acid)
HepatosplenomegalyThere are few qualitative studies about the effects of mastocytosis on daily life. However, a Danish study from 2018 describes the multidimensional impact of the disease on everyday life.
Prognosis: Patients with indolent systemic mastocytosis have a normal life expectancy. The prognosis for patients with advanced systemic mastocytosis differs depending on type of disease with MCL being the most serious form with short survival.
Onset: Mastocytosis is a disorder characterized by an abnormal accumulation of mast cells in the skin and other organs. The onset of mastocytosis can vary widely. It can present at any age, but it typically manifests in two main forms:

1. **Cutaneous Mastocytosis (CM):** Primarily affects the skin and is more common in children. The onset typically occurs in early childhood, often before the age of two.

2. **Systemic Mastocytosis (SM):** Involves multiple organs and is more common in adults. The onset usually occurs in middle-aged individuals, but it can develop at any age.

In both types, symptoms can range from mild to severe and may include skin lesions, itching, abdominal pain, diarrhea, anaphylaxis, and other systemic issues.
Prevalence: Mastocytosis is a rare disorder with an estimated prevalence of approximately 1 in 10,000 to 1 in 20,000 people. This condition involves an abnormal accumulation of mast cells in the skin and various other organs.
Epidemiology: The true incidence and prevalence of mastocytosis is unknown, but mastocytosis generally has been considered to be an "orphan disease"; orphan diseases affect 200,000 or fewer people in the United States. Mastocytosis, however, often may be misdiagnosed, as it typically occurs secondary to another condition, and thus may occur more frequently than assumed.
Intractability: Mastocytosis can be challenging to manage, but it is not necessarily intractable. Treatment focuses on managing symptoms and may involve medications such as antihistamines, mast cell stabilizers, and sometimes more advanced therapies. The approach to treatment varies depending on whether it is cutaneous mastocytosis, which primarily affects the skin, or systemic mastocytosis, which involves other organs. While some forms are more severe and difficult to manage, effective treatment options can significantly improve quality of life for many patients.
Disease Severity: Mastocytosis is categorized into cutaneous and systemic forms, which vary in severity.

1. **Cutaneous Mastocytosis**: Primarily affects the skin and is more common in children. It often improves or resolves with age. Symptoms might include itching, hives, flushing, and blistering.

2. **Systemic Mastocytosis**: Affects multiple organs and is more prevalent in adults. Severity can range from indolent (slow-progressing) to aggressive forms. Symptoms may include gastrointestinal issues, cardiovascular symptoms, bone pain, and an increased risk of anaphylaxis.

Severity depends on the type and extent of organ involvement, with systemic forms generally being more severe than cutaneous.
Healthcare Professionals: Disease Ontology ID - DOID:350
Pathophysiology: Mast cells are located in connective tissue, including the skin, the linings of the stomach and intestine, and other sites. They play an important role in the immune defence against bacteria and parasites. By releasing chemical "alarms" such as histamine, mast cells attract other key players of the immune defense system to areas of the body where they are needed.Mast cells seem to have other roles as well. Because they gather together around wounds, mast cells may play a part in wound healing. For example, the typical itching felt around a healing scab may be caused by histamine released by mast cells. Researchers also think mast cells may have a role in the growth of blood vessels (angiogenesis). No one with too few or no mast cells has been found, which indicates to some scientists we may not be able to survive with too few mast cells.Mast cells express a cell surface receptor, c-kit (CD117), which is the receptor for stem cell factor (scf). In laboratory studies, scf appears to be important for the proliferation of mast cells. Mutations of the gene coding for the c-kit receptor (mutation KIT(D816V)), leading to constitutive signalling through the receptor is found in >90% of patients with systemic mastocytosis.
Carrier Status: For mastocytosis:

- **Carrier Status**: Mastocytosis is not typically classified in terms of carriers because it is a condition arising from an overproduction of mast cells rather than a traditional mendelian genetic condition. It can be associated with mutations in the KIT gene, but these mutations are not inherited in a clear autosomal dominant or recessive pattern.

- **Occurrence**: Mastocytosis can occur sporadically or due to somatic mutations and varies from cutaneous forms, commonly seen in children, to systemic forms which are more common in adults.
Mechanism: Mastocytosis is a condition characterized by the accumulation of mast cells in various tissues. The mechanism involves the clonal expansion and accumulation of these cells, typically in the skin, bone marrow, liver, spleen, and gastrointestinal tract.

### Molecular Mechanisms:
1. **KIT Mutations**: The most common molecular mechanism in mastocytosis is mutations in the KIT gene. The KIT gene encodes the KIT receptor, a type of receptor tyrosine kinase. When mutated, this receptor can become constitutively activated, leading to uncontrolled mast cell proliferation. The most frequent mutation is D816V, which alters the catalytic domain of the receptor, rendering it continuously active without the need for its ligand, stem cell factor (SCF).

2. **Phosphorylation Cascades**: Once the KIT receptor is activated, it triggers a cascade of phosphorylation events involving various signaling pathways including the PI3K/AKT/mTOR pathway, the JAK/STAT pathway, and the RAS/RAF/MEK/ERK pathway. These pathways collectively contribute to cell survival, proliferation, and differentiation.

3. **Impaired Apoptosis**: Alterations in signaling pathways can also impair apoptosis (programmed cell death of mast cells), which allows for their accumulation and persistence in tissues.

4. **Secondary Mutations and Co-Pathways**: In addition to KIT, other mutations and pathways may be involved, particularly in advanced systemic mastocytosis. These can include mutations in genes such as SRSF2, TET2, ASXL1, and RUNX1, which further contribute to disease progression and the severity of manifestations.

Understanding these molecular mechanisms is critical for developing targeted therapies aimed at inhibiting aberrant KIT signaling and controlling mast cell proliferation.
Treatment: There is no cure for mastocytosis, but there are a number of medicines to help treat the symptoms:
Compassionate Use Treatment: Mastocytosis is a rare disorder characterized by an excess of mast cells in various tissues. Here are some compassionate use and off-label or experimental treatments that have been explored:

1. **Midostaurin (PKC412)**: This tyrosine kinase inhibitor has been granted approval for aggressive systemic mastocytosis and related conditions in some regions and may be available through compassionate use programs.

2. **Cladribine (2-CdA)**: Originally for hairy cell leukemia, this chemotherapy agent is sometimes used off-label for aggressive systemic mastocytosis.

3. **Imatinib (Gleevec)**: While primarily used for certain types of leukemia, imatinib may be effective in subsets of mastocytosis patients without the D816V KIT mutation.

4. **Interferon-alpha (IFN-α)**: Used off-label, this can help reduce mast cell load and improve symptoms in some patients with systemic mastocytosis.

5. **Nilotinib (Tasigna) and Dasatinib (Sprycel)**: These are other tyrosine kinase inhibitors being studied experimentally for potential use in mastocytosis, especially in cases resistant to other treatments.

Always consult with a healthcare provider for tailored medical advice and treatment plans.
Lifestyle Recommendations: For mastocytosis, lifestyle recommendations often focus on avoiding triggers that can cause mast cell activation and symptom flare-ups. Here are some general suggestions:

1. **Avoid Known Triggers**: Identify and avoid substances or conditions that trigger symptoms. Common triggers include certain foods, alcohol, temperature extremes, stress, medications, and insect stings.

2. **Dietary Modifications**: Some patients benefit from a diet low in histamine and other biogenic amines. Foods to avoid may include aged cheeses, fermented products, and processed meats.

3. **Stress Management**: Implement techniques such as meditation, yoga, or deep breathing exercises to minimize stress, which can exacerbate symptoms.

4. **Medication Management**: Work closely with healthcare providers to manage medications that can help control symptoms. Antihistamines, mast cell stabilizers, and other prescribed medications can be crucial.

5. **Skincare**: Use gentle, fragrance-free skincare products to avoid skin irritation, since skin involvement is common in mastocytosis.

6. **Temperature Regulation**: Avoid extreme temperatures and sudden temperature changes, which can trigger symptoms.

7. **Wear Medical Identification**: Consider wearing a medical ID bracelet to alert others to your condition in case of an emergency.

8. **Regular Medical Follow-Up**: Maintain regular appointments with a healthcare provider familiar with mastocytosis to monitor and manage the disease effectively.

Note: Always consult with a healthcare provider for personalized advice tailored to your specific condition and needs.
Medication: Mastocytosis is treated with various medications that aim to manage symptoms and stabilize mast cells. Commonly prescribed medications include:

1. **Antihistamines**:
- H1 antihistamines (e.g., cetirizine, loratadine) for skin symptoms like itching and hives.
- H2 antihistamines (e.g., ranitidine, famotidine) for gastrointestinal symptoms.

2. **Mast Cell Stabilizers**:
- Cromolyn sodium to reduce gastrointestinal symptoms.

3. **Leukotriene Inhibitors**:
- Montelukast or zafirlukast might be used for respiratory and skin symptoms.

4. **Corticosteroids**:
- Topical corticosteroids for skin lesions.
- Systemic corticosteroids in severe cases to reduce inflammation.

5. **Epinephrine**:
- For emergency treatment of anaphylaxis.

6. **Tyrosine Kinase Inhibitors**:
- For advanced or aggressive forms of mastocytosis, drugs like imatinib may be considered.

Always consult a healthcare provider for a treatment plan tailored to individual needs.
Repurposable Drugs: Repurposable drugs for mastocytosis include:

1. **Imatinib:** Originally developed for chronic myeloid leukemia, it has shown efficacy in a subset of mastocytosis patients with specific genetic mutations.
2. **Midostaurin:** Initially used for acute myeloid leukemia, it is also effective for advanced systemic mastocytosis.
3. **Ruxolitinib:** Used for myelofibrosis and polycythemia vera, it has potential benefits for symptoms of mastocytosis, although it's not formally approved for this use.

These drugs may help manage symptoms and improve the quality of life in patients with mastocytosis.
Metabolites: For mastocytosis, specific metabolites related to the condition include:

1. Histamine: Increased levels are often observed due to the excessive number of mast cells releasing this compound.
2. Tryptase: Elevated serum tryptase levels are commonly used as a marker for mast cell activation and burden.
3. Prostaglandin D2: This metabolite is released by activated mast cells and can be elevated in patients with mastocytosis.
4. Leukotrienes (e.g., Leukotriene E4): Elevated levels can be found and contribute to the symptoms of the disease.

Monitoring these metabolites can help in diagnosing and managing mastocytosis.
Nutraceuticals: There is limited research specifically on nutraceuticals for mastocytosis. Some general suggestions that might help support health in individuals with mastocytosis include:

1. **Quercetin**: A flavonoid that has been suggested to stabilize mast cells and reduce the release of histamines.

2. **Vitamin D**: Important for bone health, especially since mastocytosis can sometimes lead to bone abnormalities.

3. **Omega-3 fatty acids**: Known for their anti-inflammatory properties.

Remember to consult with a healthcare provider before starting any new supplements, as mastocytosis can have varying presentations and individual responses.
Peptides: Mastocytosis is a rare disorder characterized by abnormal accumulation of mast cells in the skin and other tissues. Peptides that may be involved in or influence mast cell activity include cytokines and growth factors, such as stem cell factor (SCF) which binds to the KIT receptor on mast cells, promoting their growth and survival. In nanotechnology (nan), researchers are exploring the use of nanoparticles for targeted drug delivery to mast cells, aiming to reduce side effects and increase treatment efficacy.